It's been an interesting few days for Sanofi (SNY)
and its shareholders. While the shares were thumped last week on what
was seen as disappointing guidance, Monday saw a rebound on news of
regulatory troubles at rival Novo Nordisk (NVO). Through it all, Sanofi still looks like a relative value and may in fact be one of the best bargains in the Big Pharma space.
Continue reading here:
After The Twists And Turns, Sanofi Still A Value
No comments:
Post a Comment